Novsoste BetaCath Shows Zero Rate Of Late-Stent Thrombosis START Trial
This article was originally published in The Gray Sheet
Executive Summary
Novoste Corp. appears poised for a smooth path to FDA approval for the BetaCath beta radiation system, given the 0% incidence of late-stent thrombosis in treating patients for in-stent restenosis.